Determining Molecular Drivers of Radiation Dermatitis

Active, not recruiting

Brief Summary: This study is being conducted to address key gaps in current knowledge and set the stage for rational design of strategies to prevent (pre-exposure to radiation), mitigate (post-exposure to radiation before overt signs/symptoms appear), and/or treat (post-onset of signs/symptoms) radiation dermatitis (itchy, dry skin or a rash on swollen, reddened skin).

Recruitment & Eligibility

Inclusion Criteria

Patients receiving standard-of-care postoperative radiation therapy (2-2.7 Gy per fraction) to the breast and/or chest wall for breast cancer treatment.
Tissue diagnosis of breast cancer.
Age > 18 years
Signed informed consent.
Complete blood count within normal limits within the preceding 2 weeks.

Exclusion criteria:

Induction chemotherapy or biologic therapy
Concurrent chemotherapy or biologic therapy
Autoimmune disease with skin manifestations - psoriasis, dermatomyositis, scleroderma, eczema, polymyositis
Allergy to lidocaine anesthesia
Known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding disorders, vitamin C or K deficiency, thrombocytopenia)
History of keloids or easy scarring

Exclusion Criteria

Not provided

Primary Outcome Measures

Name	Time	Method
Change in skin	Baseline, final week of radiation	A skin punch biopsy will be obtained from a visible area of skin that harbors signs of clinical radiation.

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial